Advertisement
Screener

BioVie Inc. (BIVI) Net Income (Loss) Available to Common Stockholders, Basic

2.8 / 5 stars · 68/120 Roast Me

BioVie Inc. Net Income (Loss) Available to Common Stockholders, Basic

BioVie Inc. (BIVI) reported Net Income (Loss) Available to Common Stockholders, Basic of -$33.01 million for the 12-month period ending 2024-06-30, per its 10-K filed 2024-09-30.

Financial Statements › Income Statement › Net Income

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-09-30

  • BioVie Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-06-30 was -$4.94M.
  • BioVie Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-03-31 was -$8.95M.
  • BioVie Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-12-31 was -$8.40M.
  • BioVie Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-09-30 was -$10.71M.
  • BioVie Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$33.01M.
  • BioVie Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$50.26M.
  • BioVie Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$26.08M.
Period endNet Income (Loss) Available to Common Stockholders, Basic 3 monthNet Income (Loss) Available to Common Stockholders, Basic 6 monthNet Income (Loss) Available to Common Stockholders, Basic 9 monthNet Income (Loss) Available to Common Stockholders, Basic 12 month
2024-06-30-$4.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30
-$13.90M
derived: sum of 2 quarters · filed 2024-09-30
-$22.30M
derived: sum of 3 quarters · filed 2024-09-30
-$33.01M
10-K · filed 2024-09-30
2024-03-31-$8.95M
10-Q · filed 2024-05-14
-$17.36M
derived: sum of 2 quarters · filed 2024-05-14
-$28.07M
10-Q · filed 2024-05-14
-$37.18M
derived: sum of 4 quarters · filed 2024-09-30
2023-12-31-$8.40M
10-Q · filed 2024-02-13
-$19.11M
10-Q · filed 2024-02-13
-$28.22M
derived: sum of 3 quarters · filed 2024-09-30
-$43.27M
derived: sum of 4 quarters · filed 2024-09-30
2023-09-30-$10.71M
10-Q · filed 2023-11-08
-$19.82M
derived: sum of 2 quarters · filed 2024-09-30
-$34.86M
derived: sum of 3 quarters · filed 2024-09-30
-$50.55M
derived: sum of 4 quarters · filed 2024-09-30
2023-06-30-$9.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30
-$24.15M
derived: sum of 2 quarters · filed 2024-09-30
-$39.84M
derived: sum of 3 quarters · filed 2024-09-30
-$50.26M
10-K · filed 2024-09-30
2023-03-31-$15.04M
10-Q · filed 2024-05-14
-$30.73M
derived: sum of 2 quarters · filed 2024-05-14
-$41.14M
10-Q · filed 2024-05-14
-$49.23M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31-$15.69M
10-Q · filed 2024-02-13
-$26.10M
10-Q · filed 2024-02-13
-$34.19M
derived: sum of 3 quarters · filed 2024-02-13
-$41.23M
derived: sum of 4 quarters · filed 2024-02-13
2022-09-30-$10.42M
10-Q · filed 2023-11-08
-$18.50M
derived: sum of 2 quarters · filed 2023-11-08
-$25.55M
derived: sum of 3 quarters · filed 2023-11-08
2022-06-30-$8.09M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-16
-$15.13M
derived: sum of 2 quarters · filed 2023-08-16
-$26.08M
10-K · filed 2023-08-16
2022-03-31-$7.04M
10-Q · filed 2023-05-12
-$18.00M
10-Q · filed 2023-05-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
Dare Bioscience, Inc. (DARE)United States$0.011B
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
MUSTANG BIO, INC. (MBIO)United States$0.013B
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14